Caribou Biosciences Announces Board and Executive Changes

Ticker: CRBU · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1619856

Caribou Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyCaribou Biosciences, INC. (CRBU)
Form Type8-K
Filed DateSep 3, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-composition, executive-compensation

Related Tickers: CRBU

TL;DR

Caribou Biosciences shakes up board and exec comp. New faces, new pay plans.

AI Summary

Caribou Biosciences, Inc. announced on September 1, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.

Risk Assessment

Risk Level: medium — Board and executive changes can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Players & Entities

FAQ

What specific roles have seen departures or appointments?

The filing indicates the departure of certain officers and directors, and the election of new directors, along with updates to compensatory arrangements for certain officers, though specific names and roles beyond general categories are not detailed in this excerpt.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on September 1, 2024.

What is Caribou Biosciences, Inc.'s state of incorporation?

Caribou Biosciences, Inc. is incorporated in Delaware.

Where are Caribou Biosciences, Inc.'s principal executive offices located?

Caribou Biosciences, Inc.'s principal executive offices are located at 2929 7th Street, Suite 105, Berkeley, California 94710.

What is the filing's primary purpose?

The filing is a Current Report on Form 8-K, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-09-03 16:01:18

Key Financial Figures

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Caribou Biosciences, Inc. Date: September 3, 2024 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing